121 related articles for article (PubMed ID: 37389884)
21. Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/mTOR signaling.
Luo J; Li H; Xiu J; Zeng J; Feng Z; Zhao H; Li Y; Wei W
Biomark Res; 2023 Apr; 11(1):38. PubMed ID: 37038184
[TBL] [Abstract][Full Text] [Related]
22. Safety of antisense oligonucleotide and siRNA-based therapeutics.
Chi X; Gatti P; Papoian T
Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
[TBL] [Abstract][Full Text] [Related]
23. Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma.
Karg MM; John L; Refaian N; Buettner C; Rottmar T; Sommer J; Bock B; Resheq YJ; Ksander BR; Heindl LM; Mackensen A; Bosch JJ
Mol Cancer Res; 2022 Aug; 20(8):1320-1336. PubMed ID: 35503453
[TBL] [Abstract][Full Text] [Related]
24. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector.
Koide H; Asai T; Furuya K; Tsuzuku T; Kato H; Dewa T; Nango M; Maeda N; Oku N
Biol Pharm Bull; 2011; 34(5):602-8. PubMed ID: 21532145
[TBL] [Abstract][Full Text] [Related]
26. Efficient inhibition of uveal melanoma via ternary siRNA complexes.
Xie L; Yang Y; Shen J
Int J Pharm; 2020 Jan; 573():118894. PubMed ID: 31765784
[TBL] [Abstract][Full Text] [Related]
27. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
Sun MM; Zhang MZ; Chen Y; Li SL; Zhang W; Ya GW; Chen KS
J Int Med Res; 2012; 40(5):1636-43. PubMed ID: 23206445
[TBL] [Abstract][Full Text] [Related]
29. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
30. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
Taniguchi H; Suzuki Y; Imai K; Adachi Y
Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
[TBL] [Abstract][Full Text] [Related]
31. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
[TBL] [Abstract][Full Text] [Related]
32. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
33. [ST6Gal I siRNA and antisense oligonucleotide-mediated gene silencing lowers the invasiveness potential of colonic carcinoma cells].
Yuan TH; Li MY; Li WY; Li H; Jiang ZH
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb; 27(2):136-40. PubMed ID: 17355919
[TBL] [Abstract][Full Text] [Related]
34. Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects.
Vaillant A
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146858
[TBL] [Abstract][Full Text] [Related]
35. Small interfering RNA for experimental cancer therapy.
Tong AW; Zhang YA; Nemunaitis J
Curr Opin Mol Ther; 2005 Apr; 7(2):114-24. PubMed ID: 15844618
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin.
Koide H; Asai T; Kato H; Yonenaga N; Yokota M; Ando H; Dewa T; Nango M; Maeda N; Oku N
Nanomedicine; 2015 Jan; 11(1):185-94. PubMed ID: 25240598
[TBL] [Abstract][Full Text] [Related]
37. LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway.
Ni H; Wang K; Xie P; Zuo J; Liu W; Liu C
Cell Mol Neurobiol; 2021 Jan; 41(1):79-90. PubMed ID: 32236901
[TBL] [Abstract][Full Text] [Related]
38. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.
Han A; Mukha D; Chua V; Purwin TJ; Tiago M; Modasia B; Baqai U; Aumiller JL; Bechtel N; Hunter E; Danielson M; Terai M; Wedegaertner PB; Sato T; Landreville S; Davies MA; Kurtenbach S; Harbour JW; Schug ZT; Aplin AE
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444561
[TBL] [Abstract][Full Text] [Related]
39. Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
Wang S; Allen N; Prakash TP; Liang XH; Crooke ST
Nucleic Acid Ther; 2019 Oct; 29(5):245-255. PubMed ID: 31158063
[TBL] [Abstract][Full Text] [Related]
40. Albumin-based nanostructures for uveal melanoma treatment.
Latorre A; Latorre A; Castellanos M; Lafuente-Gómez N; Diaz CR; Crespo-Barreda A; Lecea M; Cordani M; Martín-Duque P; Somoza Á
Nanomedicine; 2021 Jul; 35():102391. PubMed ID: 33794371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
